Topical psoriasis treatment has depended on corticosteroids and vitamin D analogs, both limited by how long they can safely be used. Vtama (tapinarof) introduced a steroid-free mechanism without those duration limits.
It activates the aryl hydrocarbon receptor in skin cells to downregulate IL-17 signaling, normalize barrier protein expression, and reduce oxidative stress. The once-daily cream treats plaque psoriasis in adults and, unlike corticosteroids, carries no restriction on treatment duration or body site.
Vtama has since expanded into atopic dermatitis, including young children, widening its market considerably. With no steroid-related restrictions on treatment duration or body site and no generic competition, its main challenge is displacing inexpensive generic topicals on formulary.
